NFE2L2 and neoplasm: Analysis of these data revealed that 90.4% of patients with KRASG12C mutations have a normally functioning KEAP1-NRF2 pathway, and thus will gain NRF2 activation within the tumour cells upon treatment with G12Ci drugs (Fig. 2p).